Investor Presentation
PHYTOCANNABINOID
Competitive Landscape: Peers and Competitors
COMPANIES
X Not competitors
X
12 X
Focused on CBD or THC-based
CB1 agonists for CNS
GW Pharma: Epidiolex™ (CBD)
approved 2018
Insys: Syndros™ (THC) approved
2017
Systemic Sclerosis
• Roche (Tocilizumab IL-6 receptor blocker: Ph 3 missed
primary outcome)
Bayer (Riociguat, PAH drug: Ph 2 missed primary outcome)
BI (Nintedanib, IPF drug: Ongoing Ph 3 for ILD in SSc)
BMS (Abatacept, RA drug: Ph 2 missed primary outcome)
GSK (GSK2330811 anti-oncostatin M Mab: Ph 2)
●
●
●
Dermatomyositis
Idera (TLR target: Ph 2 missed primary outcome)
Pfizer (PF-06823859 interferon beta inhibitor: Ph 2a)
Inflammation in CF
Celtaxys (acebilustat LTA4 hydrolase inhibitor: Ph 2 missed
primary outcome)
CFTR products are not direct competitors (Vertex)
●
●
●View entire presentation